The science behind newborn stem cells & genetic screening

Our services

Cord blood

Contains hematopoietic stem cells (HSCs), the building blocks of the blood and immune systems, with a 30-year history of saving lives106

Cord tissue

Contains mesenchymal stem cells (MSCs), endothelial stem cells, and epithelial stem cells, with additional treatment options in regenerative medicine109

ReadyGen

At-home pediatric genetic screening test that empowers parents to further protect their children by delivering personalized health information

Newborn stem cells by the numbers

80+ conditions

Newborn stem cells found in cord blood are currently being used in transplant medicine to treat over 80 conditions, including certain cancers, blood disorders, and metabolic disorders.34

40,000+ transplants

Cord blood has been used in more than 40,000 stem cell transplants worldwide, from both public donor and private family banks, to help rebuild healthy blood and immune systems.106

500+ clinical trials

Over 500 clinical trials are in progress worldwide studying cord blood and cord tissue’s role in advancing transplant medicine along with their potential applications in regenerative medicine.

100% chance

Your baby is always a 100% match to their own newborn stem cells, while full siblings have up to a 75% chance of being at least a partial genetic match.

80%+ samples used in regenerative therapies

More than 80% of the cord blood used by CBR client families has been for experimental regenerative medicine applications, like cerebral palsy and autism.138

The transformative power of regenerative medicine

Newborn stem cells are currently being studied to determine their unique role in potentially regenerating or facilitating the repair of cells.

Cord blood

Hematopoietic stem cells (HSCs) have the potential to:

  • Help improve organ and tissue damage caused by age, disease, or trauma108
  • Slow the progression of degenerative disease108
  • Be used in gene therapy treatments135-136

Cord tissue

Mesenchymal stem cells (MSCs) have the potential to:

  • Reduce inflammation107
  • Treat burns, wounds, vascular damage, and respiratory complications due to COVID-19133
  • Modulate the immune system to help improve autoimmune disorders107,108

Areas of research within regenerative medicine

The impact of transplant medicine today

Cord blood is a source of newborn stem cells that is currently being used in transplant medicine to replace damaged blood and immune systems with healthy cells.

Proven transplant medicine uses:

Blood disorders

  • Acute Myelofibrosis
  • Agnogenic Myeloid Metaplasia (Myelofibrosis)
  • Amyloidosis
  • Aplastic Anemia (Severe)
  • Beta Thalassemia Major
  • Blackfan-Diamond Anemia
  • Congenital Amegakaryocytic Thrombocytopenia (CAT)
  • Congenital Cytopenia
  • Congenital Dyserythropoietic Anemia
  • Dyskeratosis Congenita
  • Essential Thrombocythemia
  • Fanconi Anemia
  • Glanzmann’s Thrombasthenia
  • Myelodysplastic Syndrome
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Polycythemia Vera
  • Pure Red Cell Aplasia
  • Refractory Anemia with Excess Blasts in Transition (RAEB-T)
  • Refractory Anemia with Ringed Sideroblasts (RARS)
  • Shwachman-Diamond Syndrome
  • Sickle Cell Disease

Cancers

  • Acute Biphenotypic Leukemia
  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
  • Acute Undifferentiated Leukemia
  • Adult T Cell Leukemia/Lymphoma
  • Chronic Active Epstein Barr
  • Chronic Lymphocytic Leukemia (CLL)
  • Chronic Myelogenous Leukemia (CML)
  • Ewing Sarcoma
  • Hodgkin’s Lymphoma
  • Juvenile Chronic Myelogenous Leukemia (JCML)
  • Juvenile Myelomonocytic Leukemia (JMML)
  • Myeloid/Natural Killer (NK) Cell PrecursorAcute Leukemia
  • Non-Hodgkin’s Lymphoma
  • Prolymphocytic Leukemia
  • Plasma Cell Leukemia
  • Chronic Myelomonocytic Leukemia (CMML)
  • Leukocyte Adhesion Deficiency
  • Multiple Myeloma
  • Neuroblastoma
  • Rhabdomyosarcoma
  • Thymoma (Thymic Carcinoma)
  • Waldenstrom’s Macroglobulinemia
  • Wilms Tumor

Immune disorders

  • Adenosine Deaminase Deficiency (SCID)
  • Bare Lymphocyte Syndrome (SCID)
  • Chediak-Higashi Syndrome (SCID)
  • Chronic Granulomatous Disease
  • Congenital Neutropenia
  • DiGeorge Syndrome
  • Evans Syndrome
  • Fucosidosis
  • Hemophagocytic Lymphohistiocytosis (HLH)
  • Hemophagocytosis Langerhans’ Cell Histiocytosis (Histiocytosis X)
  • IKK Gamma Deficiency (NEMO Deficiency)
  • Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) Syndrome
  • Kostmann Syndrome (SCID)
  • Myelokathexis
  • Omenn Syndrome (SCID)
  • Phosphorylase Deficiency (SCID)
  • Purine Nucleoside (SCID)
  • Reticular Dysgenesis (SCID)
  • Severe Combined Immunodeficiency Diseases (SCID)
  • Thymic Dysplasia
  • Wiskott-Aldrich Syndrome
  • X-linked Agammaglobulinemia
  • X-Linked Lymphoproliferative Disorder
  • X-Linked Hyper IgM Syndrome

Metabolic disorders

  • Congenital Erythropoietic Porphyria (Gunther Disease)
  • Gaucher Disease
  • Hunter Syndrome (MPS-II)
  • Hurler Syndrome (MPS-IH)
  • Krabbe Disease
  • Lesch-Nyhan Syndrome
  • Mannosidosis
  • Maroteaux-Lamy Syndrome (MPS-VI)
  • Metachromatic Leukodystrophy
  • Mucolipidosis II (I-cell Disease)
  • Neuronal Ceroid Lipofuscinosis (Batten Disease)
  • Niemann-Pick Disease
  • Sandhoff Disease
  • Sanfilippo Syndrome (MPS-III)
  • Scheie Syndrome (MPS-IS)
  • Sly Syndrome (MPS-VII)
  • Tay Sachs
  • Wolman Disease
  • X-Linked Adrenoleukodystrophy

CBR kicks off COVID-19 treatment research.

In uncertain times, protecting your family's future health is more important than ever. Newborn stem cells help to regulate inflammation and may help treat damage from severe COVID-19.133 CBR has partnered with immunotherapy leaders to research and find treatment opportunities.

CBR clinical trials and stem cell research

Successful treatments have paved the way for further research, and today, FDA-regulated clinical trials are exploring the use of a child’s own newborn stem cells for conditions that currently have no cure.36 Potential treatments being evaluated today include:

Actionable insights into your child's health

ReadyGen is an at-home pediatric screening test that empowers parents to further protect their children by delivering personalized health information on many conditions that can't be detected by standard prenatal tests or state newborn screenings*. Through our partnership with Semna4, a health intelligence company using advanced genomic testing, families will receive two tests for the price of one.

*Worldwide, approximately 1 in 27 children screen positive for a genetic condition on the ReadyGen panel. If your child screens positive, a genetic counselor will contact you to discuss the results of the test and help you navigate next steps. The chance of a positive result varies depending on ethnicity.

A physician’s perspective

"There are only two things that (you can) potentially buy your new baby that are lifesaving: One is a good car seat, and the other is cord blood."

Dr. Marra Francis, OB/GYN

CBR Medical Consultant

Have more questions?

Our Newborn Stem Cell Educators would love to help!

888.932.6568
Chat now

Preserve with CBR

Take advantage of this once-in-a lifetime opportunity.